With Resolution No. XII/5056 of September 29, 2025, the Lombardy Region updated its Rare Disease Network, identifying new reference centers for diagnosis and treatment, including systemic amyloidosis.
The IRCCS Galeazzi-Sant'Ambrogio Hospital is now recognized as a reference center and prescriber for transthyretin amyloidosis (ATTR), guaranteeing patients an integrated pathway that combines diagnosis, therapy, and continuous monitoring.
"Patients can be treated entirely within our facility, with standards that comply with international guidelines," explains Prof. Daniele Andreini, Head of University Cardiology and Cardiac Imaging.
Why Galeazzi-Sant’Ambrogio has been recognized
The center meets the criteria set out in the regulations: clinical experience, advanced technologies, multidisciplinary team, and continuous care. Among the facilities available:
- Clinic dedicated to the myocardium and pericardium;
- echocardiography, magnetic resonance imaging, and multimodal imaging;
- team specializing in the management of cardiac amyloidosis.
Transthyretin amyloidosis
ATTR is a rare disease caused by the accumulation of transthyretin protein, which can deposit in the heart, causing thickening of the heart muscle and heart failure. Early diagnosis allows for targeted therapies and better clinical outcomes.
Therapeutic pathway and innovative drugs
Patients at the center have access to AIFA-approved drugs that stabilize transthyretin and slow the progression of the disease. The complete program, covered by the National Health Service, includes prescription, clinical follow-up, and instrumental monitoring at no additional cost.
The IRCCS Galeazzi-Sant'Ambrogio thus confirms its role as a national leader in the treatment of complex heart diseases, combining research and innovation for patients.
